收费全文 | 20075篇 |
免费 | 1476篇 |
国内免费 | 29篇 |
耳鼻咽喉 | 292篇 |
儿科学 | 559篇 |
妇产科学 | 420篇 |
基础医学 | 2787篇 |
口腔科学 | 278篇 |
临床医学 | 2536篇 |
内科学 | 3931篇 |
皮肤病学 | 316篇 |
神经病学 | 2096篇 |
特种医学 | 563篇 |
外国民族医学 | 2篇 |
外科学 | 2362篇 |
综合类 | 193篇 |
一般理论 | 17篇 |
预防医学 | 2259篇 |
眼科学 | 495篇 |
药学 | 1260篇 |
中国医学 | 49篇 |
肿瘤学 | 1165篇 |
2023年 | 131篇 |
2022年 | 230篇 |
2021年 | 665篇 |
2020年 | 313篇 |
2019年 | 532篇 |
2018年 | 547篇 |
2017年 | 445篇 |
2016年 | 445篇 |
2015年 | 494篇 |
2014年 | 758篇 |
2013年 | 983篇 |
2012年 | 1529篇 |
2011年 | 1542篇 |
2010年 | 750篇 |
2009年 | 724篇 |
2008年 | 1201篇 |
2007年 | 1213篇 |
2006年 | 1187篇 |
2005年 | 1133篇 |
2004年 | 1134篇 |
2003年 | 1028篇 |
2002年 | 943篇 |
2001年 | 212篇 |
2000年 | 179篇 |
1999年 | 219篇 |
1998年 | 197篇 |
1997年 | 152篇 |
1996年 | 154篇 |
1995年 | 134篇 |
1994年 | 112篇 |
1993年 | 103篇 |
1992年 | 128篇 |
1991年 | 143篇 |
1990年 | 131篇 |
1989年 | 132篇 |
1988年 | 115篇 |
1987年 | 133篇 |
1986年 | 131篇 |
1985年 | 116篇 |
1984年 | 100篇 |
1983年 | 81篇 |
1982年 | 67篇 |
1981年 | 71篇 |
1980年 | 75篇 |
1979年 | 61篇 |
1978年 | 53篇 |
1977年 | 55篇 |
1976年 | 51篇 |
1975年 | 71篇 |
1970年 | 51篇 |
Background
Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.Objectives
To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.Methods
Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.Results
Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.Conclusions
These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study. 相似文献Methods: A retrospective cohort design and data from two US healthcare claims repositories were employed. The study population included patients who had non-metastatic cancer of the breast, colon/rectum, lung or ovaries, or non-Hodgkin’s lymphoma (NHL), and who received myelosuppressive chemotherapy regimens with an intermediate/high risk for FN. For each patient, the first cycle of the first course was characterized in terms of PP-CSF use and FN episodes. Crude incidence proportions for PP-CSF and FN during the first cycle were estimated by calendar quarter (2010–2016); multivariable logistic regression models were used to estimate quarter-specific adjusted mean probabilities of FN by PP-CSF use.
Results: The study population totaled 142,730 patients with breast cancer (61%), colorectal cancer (14%), NHL (11%), ovarian cancer (10%) or lung cancer (5%). PP-CSF use increased from 52% in 1Q2010 to 58% in 4Q2016; pegfilgrastim was the most commonly used agent (>96% across quarters). PP-CSF administration on the same day as chemotherapy ranged from 8 to 11% until 1Q2015, and increased to 64% by 4Q2016. Adjusted incidence proportions for FN in the first chemotherapy cycle ranged from 2.7% (95% CI: 2.3–3.0) to 3.7% (95% CI: 3.1–4.3) among those who did not receive PP-CSF, and was 2.6% (95% CI: 2.5–2.7) across quarters among those who received PP-CSF.
Conclusions: Although the use of PP-CSF is commonplace in current US clinical practice, underutilization in cancer patients receiving chemotherapy regimens with an intermediate/high risk for FN may still be an issue. Use of same-day PP-CSF increased markedly from the end of 2015, although this finding reflects (at least in part) increased uptake of pegfilgrastim delivered via an on-body injector as well as the recent change in clinical practice guidelines. Overall, patients receiving PP-CSF appear to have a lower risk of FN during the first cycle of chemotherapy. 相似文献